Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1177 - 1182
Section III - Un futur en développement
Published online 15 December 2009
  1. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30. [Google Scholar]
  2. Beck A, Wurch T, Corvaïa N. Therapeutic antibodies and derivatives : from the bench to the clinic. Curr Pharm Biotechnol 2008; 9 : 421–2. [Google Scholar]
  3. Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009; 1 : 1–11. [Google Scholar]
  4. Reichter J. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21 : 1–7. [Google Scholar]
  5. Aggarwal S. What’s fueling the biotech engine-2007. Nat Biotechnol 2008; 26 : 1227–33. [Google Scholar]
  6. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 : 3992–5. [Google Scholar]
  7. Sheridan C. EGFR inhibitors embrace KRAS. Nat Biotechnol 2008; 26 : 839–40. [Google Scholar]
  8. Rosenfeld PJ. Intravitreal avastin : the low cost alternative to lucentis ? Am J Ophthalmol 2006; 142 : 141–3. [Google Scholar]
  9. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355 : 1409–12. [Google Scholar]
  10. Dobson R. NICE introduces cost sharing scheme for sight drug. Br Med J 2008; 337 : a1487. doi : 10.1136/bmj.a1487. [Google Scholar]
  11. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26 : 985–90. [Google Scholar]
  12. Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008; 49 : 389–99. [Google Scholar]
  13. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.